

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
**WO 2005/079877 A1**

(51) International Patent Classification<sup>7</sup>: **A61L 15/60**,  
17/06, 27/22, 15/32

NG13 8EU (GB). NASI, Wael [IQ/GB]; 121 Althorpe  
Drive, Loughborough, Leicestershire, LE11 4QT (GB).

(21) International Application Number:  
PCT/GB2005/000566

(74) Agents: **JONES, Stephen, Anthony** et al.; Adamson  
Jones, BioCity Nottingham, Pennyfoot Street, Nottingham  
NG1 1GF (GB).

(22) International Filing Date: 17 February 2005 (17.02.2005)

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
0403406.2 17 February 2004 (17.02.2004) GB

(71) Applicant (for all designated States except US): **ADVANCED PROTEIN SYSTEMS LIMITED** [GB/GB];  
Library House, Kett House, 1 Station Road, Cambridge  
CB1 2JX (GB).  
(72) Inventors; and  
(75) Inventors/Applicants (for US only): **HARRIS, Roy**  
[GB/GB]; 48 Chaworth Road, Bingham, Nottinghamshire

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

*[Continued on next page]*

(54) Title: WOUND DRESSINGS COMPRISING A PROTEIN POLYMER AND A POLYFUNCTIONAL SPACER



WO 2005/079877 A1

(57) Abstract: There is described a method of forming a wound dressing. The method comprises forming a protein polymer by reacting a protein with a polyfunctional spacer, or an activated derivative thereof. The polyfunctional spacer is preferably a poly-carboxylic acid, especially a dicarboxylic acid, and protein polymers prepared using such spacers are suitable for a wide range of therapeutic applications, including use as wound dressings, for the delivery of therapeutically active agents to the body and as bioadhesives and sealants.



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,*

*BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

- *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## WOUND DRESSINGS COMPRISING A PROTEIN POLYMER AND A POLYFUNCTIONAL SPACER

This invention relates to the field of wound care, and in particular to the formation  
5 of protein polymer gels suitable for topical administration as wound dressings.  
The invention also relates to the field of drug delivery, and in particular to  
processes and compositions for the delivery of therapeutic agents either  
intravenously or topically. The invention also describes a process for preparing  
protein carrier systems for the attachment or inclusion of therapeutic agents for the  
10 treatment of disease states, management of bleeding and tissue repair.

The invention relates to the formation of a range of drug delivery vehicles, from  
soluble small protein polymers to gels, using an easily-performed chemical  
procedure. The process is simple and scaleable for commercial use.

15 Soluble polymers can be used to target specific sites in the body and deliver one  
or more therapeutically active agents, from small drugs to large proteins.  
Attachment of the active agent to the polymer is preferably by chemical linkage, or  
by adsorption, or by inclusion of the active agent into the polymer during formation.  
20 More than one agent can be delivered on the same polymer.

The invention also relates to the formation of gels suitable for topical  
administration, eg to external wounds, burns and ulcers amongst other  
applications. The application can be either as an inclusion to a bandage, or as a  
25 dressing, or as a spray or solution applied directly to the skin and allowed to gel.  
The gels may also be used internally as vehicles for the slow or controlled release  
of drugs, and may also be used to prevent or inhibit tissue adhesions following  
surgical procedures, by forming a barrier between adjacent tissue membranes.

30 This invention also describes the formation of compounds suitable for the coating  
of surgical implements, eg catheters or stents, and glass or plastic plates for

diagnostic (eg ELISA, ELISPOT) or processing purposes, eg for use in the growing of cells, including stem cells.

The invention also describes the formation of a "natural" tissue sealant with or

5 without the addition of haemostatic and/or clotting agents.

The selection of a wound dressing is complex. The choice of suitable dressing for a patient requires careful and accurate assessment of the wound, knowledge of the healing process, and specific knowledge of the properties of the many

10 dressings available on the market. Patient and economic factors must also be taken into account.

Without careful consideration of all the factors, dressing selection is likely to be arbitrary and potentially ineffective.

15 It is widely accepted that a warm, moist wound environment encourages healing and prevents tissue dehydration and cell death. Most modern wound care products are designed to provide these conditions.

20 There are several types of wound care dressings available. Among those that are most commonly used are hydrogels, hydrocolloids, alginates, polymer films and polymer foams. Each product type has general characteristics but the construction and therefore performance of each particular brand may vary considerably within a particular product type. No single product is suitable for use

25 in all wound types or at all stages of healing.

The major characteristics of a dressing that determine its suitability for application to a particular type of wound include its conformability to the body (desirable to maintain complete wound closure), fluid and odour absorbing characteristics,

30 handling and adhesive properties, and the presence of antibacterial and haemostatic activity where appropriate. Other factors which may influence product selection include the potential for the dressing to cause sensitivity reactions, the

ease of application and removal (important in minimising pain and trauma to wound surface) and the interval between dressing changes. Dressings should not shed particles or fibres that may delay healing or predispose the wound to infection. They should also not contain extractables that may have an adverse

5 effect of cell growth.

Complete packing of a deep wound is important for moist interactive wound healing ensuring a bacterial barrier and decreased infection rates, decreasing moisture loss, and minimising pain. In ensuring that a cavity is completely packed,

10 dressings are often forced into the wound, further damaging the tissue.

Hydrogel wound dressings are particularly useful for burns, ulcers and deep wounds such as pressure sores because, amongst other things, they soothe pain, give a cooling sensation and provide control of wound surface hydration. Unlike

15 many alginate dressings, they do not stick to the wound and can be removed easily without pre-soaking. However, although easy to use, it is often difficult to completely fill a wound cavity with a hydrogel dressing (eg when packing leg ulcers), and so hydrogel dressings often provide a poor barrier against bacteria and may not be suitable for use on infected wounds.

20 There clearly exists a need for improved wound dressings that exhibit a greater number of desired characteristics, being more "universal", in that they are suitable for a wider range of wound types and stages of healing.

25 In particular, a dressing with the benefits of a hydrogel dressing, but superior anti-bacterial properties and the ability to completely fill wound cavities of any shape and size would provide a valuable improvement over current hydrogels.

30 Furthermore, a wound dressing that also delivers active ingredients, eg drugs to the wound site in a controlled manner would be of additional benefit. Desirable active ingredients may help to fight or protect against infection, reduce pain, reduce inflammation and/or facilitate healing, eg by encouraging clotting.

Human serum albumin (HSA) protein has been found to exhibit a number of properties that make it particularly beneficial for wound healing. For example, by reversibly binding a wide range of drug molecules, HSA may offer a controlled release mechanism for drug delivery. HSA binds metal ions (eg zinc, copper and silver), which may be important in the anti-infective treatment of wounds, and may detoxify the wound site and scavenge free radicals. Pathological platelet aggregation is inhibited by HSA, and inflammatory chemical levels (and therefore itching) are also decreased. HSA is non-allergenic and may naturally confer anti-bacterial/antiviral activity at the wound site.

Albumin is employed for a number of other medical uses, eg to increase blood volume. WO 99/66964 relates to albumin-based compositions for use as bioadhesives, surgical sealants, and implantable devices for drug delivery and prosthesis. The adhesive properties of these compositions make them unsuitable for use as external wound dressings and, although the compositions are intended to break down in the body, suitability for internal use is also limited by unwanted adhesion. Following surgical procedures, an adhesive intended to re-join damaged tissue may also attach the wound site to adjacent tissues/organs and cause further damage.

WO 99/66964 discloses the use of accessory molecules to alter the rate and/or degree of cross-linking between albumin molecules. It is stated that dicarboxylic acids are able to accelerate the gelation of bovine serum albumin. However, we have found that products formed in accordance with WO99/66964 are dry and brittle in comparison to the polymers of the present invention. Such brittle products are unsuitable for use as wound dressings.

There has now been devised a method of forming a wound dressing that overcomes or substantially mitigates the above-mentioned and/or other disadvantages associated with the prior art.

According to a first aspect of the invention there is a method for the formation of a wound dressing, which method comprises forming a protein polymer by reacting a protein with a polyfunctional spacer, or an activated derivative thereof.

- 5 The wound dressing may be formed *in situ*. By "*in situ*" is meant in the context of the present invention that reaction of the protein with the polyfunctional spacer to form the dressing occurs at the wound site. The components of the composition may be applied to the wound site simultaneously or in quick succession, or the components may be mixed immediately prior to use and the mixture then applied
- 10 to the wound site.

*In situ* formation of the wound dressing is particularly advantageous in that the dressing takes on the exact shape of the wound, completely filling the wound cavity without aggravating the exposed tissue. The precise fit ensures that the

- 15 wound is totally sealed.

Supporting substrates may be incorporated into the dressing *in situ* by addition to the composition before gelling occurs or during the gelling process. In particular, it may be preferable to cover the composition with a vapour-permeable membrane

- 20 that will prevent the polymer gel from drying out and, most importantly, keep the wound moist. The vapour-permeable membrane would preferably be added at the end of the gelling process so that it is firmly and evenly attached but does not sink too far into the composition.

25 The wound dressings of the present invention may also be pre-formed (ie cross-linked before application to the wound site). Such dressings may take the form of bandages impregnated with the protein polymer, or gel sheets, either with or without a supporting substrate. Gels of particular shapes and sizes may be specifically moulded for particular wound types or body areas. Alternatively,

- 30 appropriately sized dressings may be cut to size from larger gel sheets immediately before application.

By a "protein polymer" is meant in the context of the present invention a polymeric species made up of a plurality of complete protein units linked together by linking groups derived from the polyfunctional spacer. It will be appreciated that an individual protein molecule is "polymeric" in the sense of being made up of a chain 5 of amino acid residues that are covalently bound together. Such an individual protein molecule is not a "protein polymer" within the meaning of that term as used herein. Instead, the protein polymer is the reaction product generated by the coupling together of individual protein molecules to form a chain or matrix of such molecules covalently bound together via linking groups.

10

Proteins that may be used as in the present invention include globular proteins and fibrous or structural proteins, and mixtures thereof.

Examples of globular proteins include synthetic or natural serum proteins, natural 15 or synthetic derivatives thereof, salts, enzymatically, chemically, or otherwise modified, cleaved, shortened or cross-linked, oxidised or hydrolysed derivatives or subunits thereof. Examples of serum proteins are albumin,  $\alpha$ -globulins,  $\beta$ -globulins,  $\gamma$ -globulins, fibrinogen, haemoglobin, thrombin and other coagulation factors. Examples of fibrous or structural proteins include synthetic or natural 20 collagen, elastin, keratin, fibrin, and fibronectin, natural or synthetic derivatives thereof, and mixtures thereof.

Particularly preferred proteins are albumins.

25 Where the protein polymers prepared in accordance with the invention are intended for administration to the human body, the protein used is preferably of human origin, ie actually derived from humans, or is identical (or substantially so) in structure to protein of human origin. A particularly preferred protein is thus human serum albumin.

30

Human serum albumin may be serum-derived, for instance obtained from donated blood. Human serum albumin is readily available as a fractionated blood product

and has been safely used for many years for intravenous delivery as a blood expander. However, in order to eliminate or reduce the risk of transmission of potential contaminants, eg viral or other harmful agents, that may be present in blood-derived products, as well the potential limitations on supply associated with

5 material isolated from donated blood, the protein, eg human serum albumin, may be a recombinant product derived from microorganisms (including cell lines), transgenic plants or animals that have been transformed or transfected to express the protein.

10 For veterinary use, non-human animal-derived protein may be used, as appropriate. Examples of such proteins include horse serum albumin, dog serum albumin etc.

Mixtures of proteins, ie more than one different protein, may be used.

15 Functional groups on the protein molecules with which the spacer may react include amino groups. Preferred proteins therefore include proteins with relatively high proportions of amino acid residues that include free amino groups, particularly NH<sub>2</sub> groups. One example of such an amino acid residue is lysine, and so

20 particularly preferred proteins for use in the invention include proteins including lysine residues, especially proteins with high proportions of lysine residues, eg more than 20 lysine residues per protein molecule, more preferably more than 30 or more than 40 lysine residues.

25 Polyfunctional spacers that may be used in the present invention include polycarboxylic acids, polyamines, poly(carboxy/amino) compounds (ie compounds having a multiplicity of carboxyl and amino groups), polyalcohols, polyketones, polyaldehydes, and polyesters.

30 Polycarboxylic acids or polyamine spacers are preferred, more preferably dicarboxylic acids or diamines.

Polycarboxylic acids include citric acid and polyacrylic acid.

Preferred spacers are bifunctional spacers, particularly homobifunctional spacers.

5 Polyamines include poly(lysine) and chitosan

Particularly preferred spacers are dicarboxylic acids.

The dicarboxylic acid spacer is most preferably an alkylene dicarboxylic acid,

10 particularly a straight-chain alkylene dicarboxylic acid molecule of the formula:



in which n is from 1 to about 20. Preferably n is from 2 to 12, more preferably from

15 3 to 8.

Preferred straight-chain alkylene dicarboxylic acid spacers are:

n	Common name	Systematic name	Formula
2	Succinic Acid	Butanedioic Acid	$\text{HOOC}(\text{CH}_2)_2\text{COOH}$
3	Glutaric Acid	Pentanedioic Acid	$\text{HOOC}(\text{CH}_2)_3\text{COOH}$
4	Adipic Acid	Hexanedioic Acid	$\text{HOOC}(\text{CH}_2)_4\text{COOH}$
5	Pimelic Acid	Heptanedioic Acid	$\text{HOOC}(\text{CH}_2)_5\text{COOH}$
6	Suberic Acid	Octanedioic Acid	$\text{HOOC}(\text{CH}_2)_6\text{COOH}$
7	Azelaic Acid	Nonanedioic Acid	$\text{HOOC}(\text{CH}_2)_7\text{COOH}$
8	Sebacic Acid	Decanedioic Acid	$\text{HOOC}(\text{CH}_2)_8\text{COOH}$

20 Straight-chain alkylene dicarboxylic acids are particularly useful spacers because the properties of the resulting protein polymers may be varied simply by varying the length of the alkylene chain. In general, at a fixed protein concentration the gelling time decreases and the polymers become harder, less rubbery and more turbid with increasing dicarboxylic acid chain length. The chemistry is simple, yet

a wide range of protein polymer systems may be prepared by adjustment of only a small number of variables. As well as promoting a high degree of control, the properties of the polymers can be anticipated reasonably well from the composition and reaction conditions.

5

In order to facilitate reaction of the spacers with the protein molecules, it will generally be desirable for the spacer to be activated, ie for the functional groups of the spacer to be converted to groups of greater reactivity towards groups in the protein. Suitable activation chemistries will be familiar to those skilled in the art, 10 and include the formation of active ester groups.

One particular class of activators, suitable for use with dicarboxylic acid spacers, is carbodiimide compounds, and a particularly preferred activator for use in the invention is ethyl[dimethylaminopropyl]-carbodiimide (EDC). In one embodiment 15 of the invention the dicarboxylic acid (preferably C6-C10 in length) is added to the protein solution. EDC is added to the mixture and the reaction is allowed to proceed. The concentration of the protein solution, the proportion of dicarboxylic acid to protein, the amount of EDC and the time are all important to the desired result. The EDC activates -COOH groups and allows linking with free amine 20 groups on the protein.

The control of the reaction means that the polymerisation can be controlled to give soluble polymers, insoluble particles or gels from the same reaction mixture. Greater than 95% conversion of the starting protein concentration to a polymer 25 may be obtained, and up to 100% conversion into a gel.

The omission of the dicarboxylic acid spacer, and the use of EDC alone (under the conditions described here), leads only to partial polymerisation over a period of several hours to days, with a lower yield of polymer compared to that obtained 30 when a dicarboxylic acid is used.

In general, the method according to the invention will be carried out in solution. Preferably, an activating agent, eg EDC, is added to a solution of the protein and the dicarboxylic acid. The EDC may be in solution, eg with distilled water, or it may be added to the protein and dicarboxylic acid solution in a solid form, eg powder.

- 5 Although in principle it is also possible to firstly activate the dicarboxylic acid with EDC and then to add the activated spacer to the protein solution, this has been found in practice not to produce results as good as those obtained by adding EDC to the mixture of protein and spacer.
- 10 For ease of application, it may be desirable to formulate the reactants as a mixed dry powder to which water, saline or a buffer solution is added immediately prior to application. The protein and dicarboxylic acid may not react without addition of EDC so, in order to store the reagents as powders without risk of premature reaction, it may be desirable keep the protein/dicarboxylic acid powder separate from the EDC powder, eg by containment in separate sachets. A preferred method of application is a syringe containing a solution of the protein/dicarboxylic acid solution and EDC powder, the solution and the powder being separated by a frangible membrane. By pressing the plunger of the syringe, the user forces the membrane to rupture and the reagents to mix immediately prior to application.
- 15
- 20 Application of solutions to a wound site may be by pouring, painting or spraying of the solutions.
- 25 It may be desirable for a wound dressing to deliver therapeutically active ingredients to the wound site. Drugs such as antibiotics, antivirals, anti-inflammatory agents, haemostatic agents, pain killers and phages may be added directly to the composition or via carriers that promote absorption from the wound site, eg liposomes. Actives that promote or improve tissue repair may also be incorporated, eg growth factors, anti-scarring agents, and agents that promote angiogenesis. By eliminating infection and absorbing exudates, the smell of malodorous wounds can be reduced. However, wound odour may also be
- 30

reduced/removed by incorporating agents (eg charcoal) into the dressing which absorb the volatile molecules that are responsible for the smell.

The incorporated active compounds will be delivered to the wound site by leaching  
5 from the gel and by release from the gel as it degrades. A key factor in determining the rate of release of an active will be the softness/hardness of the protein polymer. Active compounds will leach out of softer polymers more easily because they are not held in as effectively by the cross-linking protein molecules. Softer polymers will also break down at a faster rate because the looser structure  
10 will allow moisture and enzymes to penetrate more easily.

According to another aspect of the invention, there is provided a wound dressing prepared by the methods described above, ie a wound dressing comprising a protein polymer formed by reacting a protein with a polyfunctional spacer or an  
15 activated derivative thereof.

The particularly preferred chemistry of the present invention has also been found to produce protein polymers that are suitable for a number of other therapeutic applications.

20 Thus, according to another aspect of the invention, there is provided a method of forming a protein polymer, which method comprises reacting a protein with a dicarboxylic acid or an activated derivative thereof, provided that the protein is not bovine serum albumin.

25 A further aspect of the invention is a method of forming a protein polymer, which method comprises reacting a protein with an alkylene dicarboxylic acid or an activated derivative thereof.

30 The protein is preferably an albumin, particularly human serum albumin.

By appropriate choice of reactants and reaction conditions, products with a wide variety of properties can be prepared. Thus, the protein polymers may be prepared in soluble form, in the form of insoluble particles, or in gel form. The gel form can be varied from very sticky to soft but non-adhesive, and the hardness

5 can be incrementally increased up to very hard gels with low deformation.

Parameters that can be varied to achieve these differing results include the choice of protein starting material, the choice of spacer, concentrations of the various reactants, the reaction temperature and duration of the various reaction steps.

10 The speed of gel formation can also be varied over a wide range, from seconds to minutes to hours, by controlling the ratio of reagents used to form the gel and the temperature.

15 The gelling reaction is best performed at mildly acidic pH (eg pH=5-6). However, it is often preferable to raise the final pH of the gel to close to physiological pH.

20 There are a number of ways of controlling the pH of the final gel. One approach is to vary the molar ratio of protein to dicarboxylic acid; low levels of dicarboxylic acid give gels of close to physiological pH. A second approach is to vary the molar ratio of protein to EDC; high EDC levels result in gels of higher pH. For those skilled in the art it can be seen that it is possible to find a balance of conditions that achieves the required gel consistency for a particular application at the desired pH.

25 The gelling reaction may be a biphasic reaction where initial gelling is followed by a secondary "curing" stage. The reaction will not proceed to the curing stage for certain combinations of HSA, dicarboxylic acid and EDC, eg if the level of EDC is too low. Instead, a drop in pH is observed after gelling and the gel re-dissolves. It is thought that a minimum percentage of carboxylic acid groups must be activated by the EDC in order to drive the reaction all the way to the curing stage. Polymers with a low pH are generally less stable because of the unreacted carboxylic acid

30 groups present on the spacer and HSA.

The addition of further compounds may be advantageous. For example, the addition of drugs or other active compounds for controlled release (as described in relation to wound dressings above), and/or other modifying agents which alter the properties of the polymer, eg to release water, to affect flexibility, improve

5 absorbance, skin-feel and aesthetics, mechanical and/or adhesive strength or to alter the degradation profile of the protein polymers.

Ethanol, glucose and glycerol are examples of compounds that may be added to the protein gels of the present invention.

10

Ethanol, a well-known bacteriostat, may be added to improve the anti-bacterial properties of the gel, glucose to provide a source of energy and thereby to promote cell growth, and glycerol to help prevent moisture loss and maintain gel integrity at the wound site.

15

Glucose may be particularly useful in wound dressings of the present invention for use on chronic wounds because chronic wounds generally have a poor blood supply, hence poor energy supply and therefore poor cell growth.

20

We have found that the addition of ethanol, glycerol or glucose improves the consistency of the polymers by further reducing brittleness.

Although it is possible to add modifying agents to the HSA and dicarboxylic acid in one step, in practice (using ethanol, glucose, or glycerol) we found that it is more

25

effective to modify a percentage of the HSA with the modifying agent prior to mixing with the remaining unmodified HSA and carboxylic acid spacer. Thus, the modifying agent is added to aqueous HSA, and EDC is added to facilitate the reaction. The modified HSA and ethanol solution is added to a solution of unmodified HSA and dicarboxylic acid, and then this "gelling solution" is reacted

30

with EDC to form a gel.

As well as modification of the protein being used to improve the physical properties of the protein polymer, modified HSA may have utility as a therapeutic. De-liganded albumin, for example, has available binding sites which may trap and remove toxins, cytokines and the like.

5

Polymers may be prepared in soluble form using low protein concentrations. Soluble polymers are more easily produced at neutral pH. Low concentrations and neutral pH are easily achieved by adding a suitable buffer, eg phosphate buffered saline. Soluble polymers are suitable for parenteral delivery and have a 10 number of applications as delivery vehicles, eg delivering drugs, delivering contrast agents useful in imaging techniques, or as platelet substitutes or enhancers (delivering haemostatic agents).

The need for platelet substitutes and/or enhancers is being driven by their 15 application in the treatment of cancer patients. One of the side-effects of cancer therapy is the drastic reduction in platelets, or thrombocytopenia. The condition is currently treated with a transfusion of blood-derived platelets, but as chemotherapy regimes become even more aggressive and as the use of bone marrow transplantation increases, the requirement for platelets is growing. 20 Furthermore, blood-derived platelets have the potential to transmit viral infections, suffer from instability during storage, and cause immune reactions.

The terms 'platelet substitutes' and 'platelet enhancers' are often interchanged, whether incorrectly or for convenience. By 'platelet substitutes' in the context of 25 the present invention is meant a complete platelet replacement which does not necessarily require the presence of naturally produced platelets. 'Platelet enhancers', on the other hand, may require the natural formation for a platelet plug at the wound site (and so the natural platelet count may need to be above a threshold level). Platelet enhancers then aggregate at the platelet plug to form a 30 clot, thereby improving the activity of platelets in thrombogenic conditions. Platelet substitutes/enhancers may be prepared according to the present invention by immobilising clotting agents or other active peptide derivatives to the surface of the

polymer in such as way as to maintain their biochemical activity. In particular, protein polymers of the present invention may be conjugated with such agents that promote or regulate platelet adhesion and aggregation through specific receptors expressed on the platelet surface. An example is the GPIIb/IIIa receptor that

5 interacts with fibrinogen, active peptides of fibrinogen and von Willebrand's factor. Methods of conjugating with fibrinogen include thiolating the protein polymer, activating the fibrinogen with N-[maleimidocapric acid] hydrazide and then conjugating the activated fibrinogen via the thiol groups on the protein polymer. The platelet substitute/enhancer can be delivered by intravenous infusion and is

10 activated at the site of internal wounds in the blood vessels.

As a delivery vehicle, the protein polymers are suitable for the slow or controlled release of drugs. Furthermore, by delivery of active agents or by virtue of their absorption properties, the protein polymers of the present invention may be useful

15 for detoxification applications.

The protein polymers may naturally enhance drug delivery to areas of the body that are difficult to target independently. More preferably, the protein polymers may be conjugated with one or more targeting moieties that have an affinity with a

20 specific locus in the body. Suitable targeting moieties may be antibodies. An antibody may act as a therapeutic agent in its own right, or else one or more secondary agents may be attached, eg cytotoxics, radionuclides for targeted anticancer therapies, or vaccines or genes. A targeting moiety may have an affinity with a particular organ or site of a disease, it may enhance delivery of the

25 secondary agent to that location, and/or may alter the biodistribution of those agents, for example by causing the agent to accumulate in a particular organ, eg the liver, thereby allowing that organ to be targeted.

Similarly, protein polymers of the present invention may be bound with targeting

30 moiety and a contrast agent. Contrast agents may be metals useful in magnetic resonance imaging (MRI), or in nuclear imaging, or as therapeutic agents in radiotherapy.

Insoluble protein particles can be prepared with increased concentration of dicarboxylic acid spacer relative to the activating agent and/or increased reaction time whilst maintaining a low protein concentration. Alternatively insoluble

5 particles can be produced by dispersing soluble protein polymers of the present invention in organic solvents, eg acetone.

Using the method of the invention, protein polymer gels can be produced with differing consistencies (soft to hard), and differing adhesive strengths.

10 Non-adhesive protein gels of the present invention are useful in preventing or inhibiting tissue adhesions following surgical procedures by forming a barrier between adjacent tissue membranes. By adjustment of the reagents and reaction conditions, the speed of degradation can be chosen so that, for example, the

15 polymer can be designed to degrade as the wound heals. The *in situ* formation of the gel will ensure total coverage of a particular area, to a desirable thickness. The gel may be applied as a thin film or else the composition may be poured into a larger cavity, so as to fill the cavity.

20 Alternatively, adhesive gels of the present invention may be employed to bond tissues together, eg to seal incisions, tears, perforations and/or fluid or gaseous leaks in tissues. It is well-understood that suturing and stapling delicate tissue can cause tissue damage/weakness in itself, and consequential problems, eg leaks of biological fluids or bacterial infections. Bioadhesives have been described that

25 provide means of binding tissues. However, none of these compositions have been found to be entirely satisfactory. There still exists a need for effective bioadhesive compositions that are truly safe and efficient, and whose properties can easily be tailored to suit the nature of the tissue and the extent of the damage.

30 Similarly, the protein gels are suitable for coating prosthetics and surgical implements, eg catheters or stents. Such a coating may have bioadhesive properties that aid retention of the device in the desired location. The use of

natural proteins in the polymers, and in particular HSA, will reduce the risk of the implant being rejected by the body's natural defences against the introduction of a foreign body.

5 The protein polymers of the present invention are suitable for coating glass or plastic plates for diagnosis (eg ELISA, ELISPOT) or processing purposes, eg for use in the growing of cells, including stem cells.

Hard gels may be prepared using high levels of dicarboxylic acid spacer and/or

10 EDC. It is envisaged that hard gels of the present invention may be used to strengthen and/or repair bone or cartilage, as artificial bone implants or other prosthetic devices. The gel may be formed *in situ* or pre-formed in a mould.

The invention will now be described in greater detail, by way of illustration only,

15 with reference to the following non-limitative Examples, which demonstrate that:

- Varying the conditions of the reactions in terms of component concentration and composition, pH and time can produce the different forms of the polymers.

20 ○ Soluble polymers are more easily produced at neutral pH with lower protein concentrations.

○ Increasing the levels of spacer and activator in the reaction will produce insoluble particles, which are also produced when the soluble polymers are mixed with organic solvents.

25 ○ Increasing the protein concentration and lowering the pH of the reaction produces gels. Further, it is possible to alter the physical characteristics of the gel (soft to hard and adhesive properties) by varying the ratio of the gel components, protein concentration and pH or a combination of these factors. This is an important factor in the production of gels for therapeutic uses including wound dressings, gel implants and bioadhesives.

Abbreviations

DMSO	Dimethylsulfoxide
EDC	Ethyl[dimethylaminopropyl]carbodiimide
5	EMCH N-[maleimidocaproic acid]hydrazide
HSA	Human serum albumin
PBS	Phosphate buffered saline

Description of Figures

10

Figure 1 shows the separation of a soluble polymer of the present invention by gel filtration on a Sepharose 6B column using standard conditions, wherein the absorbance is monitored at of 280nm.

15 Figure 2 shows the release of tetracycline from a gel of the present invention over a 45 hour period.

Example 1: Formation of soluble protein polymers

20 1.1 Formation of a soluble polymer of HSA using sebacic acid

Sebacic acid (146mg) in 2.5ml DMSO was added to 10ml 20% HSA solution (BPL, Zenalb) and 20 ml 0.01M PBS buffer pH=7.4 with stirring until the solution became clear. EDC (276mg) in 7.5ml PBS buffer was added to the solution and stirred for 25 16 hours (overnight). The resulting solution was centrifuged to remove the small amount of insoluble polymer. The soluble fraction was gel-filtered on a Sepharose 6B column using standard conditions. Protein elution was monitored at  $A_{280\text{nm}}$ . The result is shown in Figure 1. Monomeric HSA elutes at ~340mls.

1.2 Preparation of a soluble polymer of HSA using adipic acid

Adipic acid 26.3mg in 1ml 50% ethanol was added to a stirred solution of 5ml 20% HSA solution (BPL,Zenalb) and 25 ml 0.01M PBS buffer, pH=7.4, with stirring until 5 the solution became clear. EDC, 69mg in 4ml PBS buffer, was added dropwise to the solution with stirring. The resulting solution was stirred for a further 2 hrs. The resulting solution was centrifuged to remove the small amount of insoluble polymer. The soluble fraction was gel-filtered on a Sepharose 6B column (as in Example 1.1 above) using standard conditions.

10

1.3 Linking of fibrinogen to soluble HSA protein polymer to produce a platelet substitute

In this example a platelet substitute (enhancer) is prepared by immobilising the 15 clotting factor, fibrinogen, to the surface of the HSA soluble polymer in such a way as to maintain the biochemical activity of the fibrinogen. The platelet substitute can be delivered by intravenous infusion and is activated at the site of internal wounds in the blood vessels.

20 1.3.1 *Preparation of soluble protein polymer*

Sebacic acid (30 mg) in 1.25 ml DMSO was added to 5ml 20% HSA solution (BPL, Zenalb) in 15 ml PBS buffer (0.01M; pH=7.4) and stirred until the solution became clear. EDC (57 mg) in 4 ml PBS buffer was added to the HSA/spacer solution and 25 stirred at room temperature for 3 hours.

Other dicarboxylic acids of varying carbon chain length can be substituted for sebacic acid in the above reaction.

### 1.3.2 *Thiolation of protein polymer*

2-iminothiolane (210 mg) was added as solid to the polymer solution, followed by incubation in the dark at room temperature for 1.5 hours. The polymer was then

5 desalted by gel filtration in 0.01M; pH=7.4 PBS solution on a Sephadex G25 column using standard conditions.

### 1.3.3 *Activation of fibrinogen for coupling to polymer*

10 Fibrinogen (750 mg) in 10 ml 0.05 M phosphate buffer was mixed with 2.5 ml 100mM sodium periodate in 0.1M sodium acetate buffer and incubated in the dark at room temperature for 30 minutes. The activated fibrinogen was then desalted in 0.01M; pH=7.4 PBS solution by gel filtration on a Sephadex G25 column. The activated sugars were reacted with a hydrazide, in this example N-

15 [maleimidocaproic acid]hydrazide (EMCH) (11 mg) for 2 hours in the dark at room temperature.

### 1.3.4 *Conjugation of activated fibrinogen with protein polymer*

The activated EMCH-fibrinogen solution was added to the iminothiolated polymer

20 solution and stirred overnight. The resulting solution was centrifuged to remove any insoluble material and then gel-filtered in 0.01M; pH=7.4 PBS solution on a Sepharose 6B column.

## Example 2: Formation of insoluble particles

25

2.1 Formation of an insoluble particle in aqueous solutions

Insoluble protein polymer particles can be prepared by methods analogous to those of Example 1, but with increased concentration of dicarboxylic acid spacer

30 and EDC and/or increased reaction time whilst maintaining low protein concentration.

HSA (1ml 20%; BPL, Zenalb) and glutaric acid were mixed in 3ml of distilled water at a molar ratio of 1/40. EDC in 1ml distilled water was added to the stirred solution in 1/120 molar ratio HSA/EDC. The solution was stirred for 3 hours at room temperature and then centrifuged. The pellet was washed with distilled water and then dried.

5

## 2.2 Formation of an insoluble particle in organic solvents

Insoluble particles can also be produced by the dispersion of soluble polymers  
10 produced in Example 1 above into organic solvents, eg acetone.

One volume of soluble polymer solution (Example 1) was mixed with 10 volumes acetone for 15 min at room temperature. The resultant particles could be collected by centrifugation or decanting.

15

## Example 3: Formation of protein polymer gels

### 3.1 Preparation of HSA polymer gel using sebacic acid and high concentration of HSA solution

20

A solution of 48.5mg sebacic acid in 1ml DMSO was added to 4ml HSA 20% solution (BPL, Zenalb). The solution was stirred until it became clear. A solution of 92mg of EDC in 2ml distilled water was added. The final concentration of HSA in the reaction was 114mg/ml. The final molar ratio of HSA/sebacic acid/EDC was  
25 1/20/40.

The resulting mixture formed a gel 30 seconds after addition of EDC.

It was noted that in an equivalent experiment to this example, but in the absence  
30 of the dicarboxylic acid, a gel was formed after 2hours. The properties of the gel in this case were not suitable for wound dressings being of a hard, brittle nature that would make them difficult to apply and remove. The time to gel *in situ* would be too long for practical use.

3.2 Preparation of HSA polymer gel using sebacic acid and low concentration of HSA solution

The same experimental procedure was used as described in Example 3.1, except  
5 that the final concentration of HSA was 72mg/ml. The final molar ratio of  
HSA/sebacic acid/EDC was 1/20/40.

The resulting mixture formed a gel in less than 5 minutes.

10 3.3 Preparation of HSA polymer gel using adipic acid and high concentration of HSA solution

Adipic acid, 35mg, was dissolved in 4ml 20% HSA solution (BPL, Zenalb).  
A solution of 92mg EDC in 2ml distilled water was added as above. The final  
15 molar ratio of HSA/adipic acid/EDC was 1/20/40.

The resulting mixture formed a soft gel polymer after 2 minutes.

3.4 Preparation of gel containing haemoglobin

20 HSA (300mg) and haemoglobin (100mg), sebacic acid (24.25mg in 0.5 ml DMSO),  
EDC (46mg in 1ml distilled water) and 2ml PBS buffer (as above) were mixed  
together to give a final protein concentration of 80mg/ml.

25 A gel was formed after 10 minutes.

Example 4: The effect of spacer length on gel characteristics

In order to determine the effects of varying the dicarboxylic acid spacer chain  
30 length, protein polymer gels were prepared using HSA at various concentrations  
and four different dicarboxylic acid spacers, with EDC as activator.

A solution of dicarboxylic acid in DMSO (120 $\mu$ moles in 250 $\mu$ l) or (90 $\mu$ moles in 250 $\mu$ l) was added to 1 ml of 20% aqueous HSA solution, in dicarboxylic acid/HSA molar ratios of 40/1 and 30/1. The solution was stirred at room temperature until it became clear. An aqueous solution of EDC was then added in EDC/dicarboxylic acid molar ratio of 2/1. The gelling time and the properties of the gels are detailed in Tables 1-3 below.

The gelling reaction is a biphasic reaction: initial gelling is followed by a secondary, "curing", stage. Gelling time relates to initial observed gelling, and gel hardness refers to the final state of the gel after "curing".

*Table 1: The effect of dicarboxylic acid chain length on gelling time using 1/40/80 HSA/dicarboxylic acid/EDC molar ratio*

HSA conc. (mg/ml)	Gelling time (sec.)			
	Glutaric acid (C5)	Adipic acid (C6)	Suberic acid (C8)	Sebacic acid (C10)
151	40	23	21	19
140	42	25	23	22
127	49	27	27	24
108	90	45	30	25
93	130	58	42	30

5

*Table 2: The effect of dicarboxylic acid chain length on gelling time using 1/30/60 HSA/dicarboxylic acid/EDC molar ratio*

HSA conc. (mg/ml)	Gelling time (sec.)			
	Glutaric acid (C5)	Adipic Acid (C6)	Suberic acid (C8)	Sebacic acid (C10)
151	46	31	29	23
140	60	35	33	26
127	75	43	38	32
108	140	60	45	37
93	240	95	62	50

10

*Table 3: The effect of HSA concentration and dicarboxylic acid chain length on gel properties using 1/40/80 HSA/dicarboxylic acid/EDC molar ratio*

HSA conc. (mg/ml)	Gel Properties			
	Glutaric acid (C5)	Adipic acid (C6)	Suberic acid (C8)	Sebacic acid (C10)
151	Hard rubbery gel, slightly turbid.	Turbid, hard, rubbery gel.	Turbid, very hard brittle gel	Very hard, turbid, brittle gel
140	Clear, hard rubbery gel	Turbid, hard, rubbery gel.	Turbid, very hard brittle gel	Very hard, turbid, brittle gel
127	Clear medium/hard rubbery gel	Turbid, hard, rubbery gel.	Turbid, hard, slightly rubbery gel	Hard, white, brittle gel
108	Very soft clear gel	Initially soft gel, hard after 3mins. Slightly turbid	Initially medium/hard turbid rubbery. After 4 min very hard, white, brittle gel	Hard, white, brittle gel
93	Very soft clear gel	Initially soft gel, medium, brittle gel after 3mins. Slightly turbid	Initially turbid, soft/medium rubbery. After 4min very hard, white gel	Hard/medium, white, brittle gel

At each HSA concentration the gelling time decreases and the gels become

5 generally harder, less rubbery and more turbid with increasing dicarboxylic acid chain length. Increasing the HSA concentration decreases the gelling time and increases the hardness of the gel.

Example 5: Control of gelling time and gel properties

Different applications of the gels will demand different gelling times and gel consistencies. Gels can be formed in seconds or over much longer periods. Gels

5 can be extremely soft and "sticky" or very hard and rubbery. There are several approaches to controlling these parameters and for any application any or all of the following approaches can be used. All gels described below were clear unless otherwise stated.

10 5.1 Control of gelling time and gel characteristics by varying the molar ratio of HSA to dicarboxylic acid spacer

Gels were produced by dissolving glutaric acid (GA) in aqueous HSA solution (20% USP) at room temperature, and then adding a solution of EDC in distilled

15 water to activate the gelling reaction. The gelling mixture was inverted gently several times to ensure complete mixing.

The molar ratio of HSA to glutaric acid was varied from 1/0 to 1/40 at two EDC concentrations. Experimental results are shown in Tables 4 and 5 below.

20

*Table 4: Effect of changing HSA/GA molar ratio (molar ratio HSA to EDC of 1:35)*

HSA/GA	Gelling time	Gel pH	Gel Properties
1/0	Over 2hrs	7.1	Soft
1/3.5	9m	6.8	Medium
1/5	5m 25s	6.5	Medium
1/10	3m 15s	5.6	Soft
1/20	3m 40s		Soft gel, redissolves after 3m
1/40			No gel formed

*Table 5: Effect of changing HSA/GA molar ratio (molar ratio HSA to EDC of 1:70)*

HSA/GA	Gelling time	Gel pH	Gel Properties
1/0	About 30m	7.6	Medium
1/3.5	4m 30s	7.2	Medium-hard
1/5	2m 45s	7.1	Medium-hard
1/10	1m 30s	6.2	Hard
1/20	1m 5s	5.3	Medium
1/40	1m 15s		Medium-soft gel, redissolves within 30m
1/50	1m 45s		Soft gel, redissolves within 5m

Initially increasing the levels of glutaric acid decreases the gelling time and 5 produces harder gels. However at higher levels of glutaric acid the gels are unstable, this can be offset by increasing the levels of EDC. This is discussed in Example 6.

#### 5.2 Control of gelling time and gel characteristics by varying the HSA concentration

Gels were prepared using the method described in Example 5.1. A molar ratio of HSA to glutaric acid of 1/5 and a molar ratio of HSA to EDC of 1/70 were used. The concentration of HSA was varied from 182mg/ml to 120mg/ml. Results are 15 shown in Table 6 below.

*Table 6: Effect of HSA concentration on gelling time and gel hardness*

[HSA] mg/ml	Gelling Time	Gel Hardness	Gel pH
182	2m 27s	Hard	7.1
166	2m 45s	Medium-hard	7.1
150	4m 12s	Medium	7.2
135	5m 55s	Medium-soft	7.3
120	7m 15s	Soft	7.2

Decreasing the concentration of HSA results in longer gelling times and softer gels.

**5.3 Control of gelling time and gel characteristics by varying the molar ratio of HSA to EDC**

10 Gels were produced as described in Example 5.1. A molar ratio of HSA to glutaric acid of 1/10 was used and the final concentration of HSA was 166mg/ml. The molar ratio of HSA to EDC was varied from 1/35 to 1/80. Results are shown in Table 7 below.

15 *Table 7: Effect of varying the HSA/EDC molar ratio*

HSA/EDC molar ratio	Gelling time	Gel pH	Gel Hardness
1/35	3m 5s	5.6	Soft
1/50	1m 50s	5.9	Medium
1/60	1m 32s	6.1	Hard
1/70	1m 23s	6.2	Hard
1/80	1m 5s	6.6	Very Hard

Table 7, and a comparison of tables 4 and 5 above, show that higher levels of EDC result in shortened gelling times and harder gels.

5.4 Control of gelling time and gel characteristics by addition of ethanol, glucose and glycerol

5 A further important approach is to prepare an HSA “gelling solution” by initially modifying the HSA by reaction with a reagent, such as ethanol, glucose or glycerol (all of which have active –OH groups) in the presence of low concentrations of EDC. The preparation of HSA gelling solution by reaction with ethanol is described below.

10

5.4.1 *Preparation of HSA gelling solution by reaction with ethanol*

Ethanol was added dropwise to a stirred solution of 20% aqueous HSA. The solution was stirred until it became clear. Solid EDC was added to the solution 15 (molar ratio HSA/EDC of 1/15) and stirred at room temperature for a minimum of 2 hours. Glutaric acid was dissolved in 20% aqueous HSA and stirred at room temperature for 30 minutes.

20 To prepare the final “gelling solution”, the modified HSA /ethanol solution was mixed with the unmodified HSA/glutaric acid solution in 1/1 volume ratio, and stirred at room temperature for 30 minutes. The final molar ratio of HSA to glutaric acid was 1/5.

25 This mixture or “gelling solution” was reacted with EDC to form the gel as in previous examples.

The volume ratio of ethanol/HSA Solution was varied from 1/7 to 1/14 results are shown in Table 8 below.

*Table 8: Effect of modified HSA/Ethanol volume ratio on gelling time and hardness of the gel*

Volume ratio HSA/Ethanol solution	Molar ratio HSA/EDC*	Gelling time	Gel Hardness
7/1	1/35	1m 45s	Hard
8/1	1/35	2m 40s	Hard
10/1	1/35	1m 50s	Medium/Hard
14/1	1/35	2m 30s	Soft
No ethanol	1/35	5m 30s	Medium/Hard

5 (\* Molar ratio of HSA to EDC added in the gelling reaction)

Initial reaction of HSA with ethanol results in a general decrease in gelling time. At low levels of ethanol softer gels are produced. However, more than 10% v/v ethanol results in harder gels. No brittleness is found in these gels; despite their  
10 hardness they remain flexible.

The experiment described in Example 5.1 was repeated using ethanol/HSA gelling solution prepared as described above, with 10%v/v ethanol and HSA/glutaric acid molar ratios in the range 1/0 to 1/40. The results are shown in Tables 9 and 10  
15 below.

*Table 9: Effect of HSA/glutaric acid molar ratio using ethanol-modified HSA (molar ratio HSA/EDC of 1/35)*

<b>Molar Ratio HSA/GA</b>	<b>Gelling time</b>	<b>pH of the gel</b>	<b>Gel Hardness</b>
1/0	About 30m	7.5	Soft
1/3.5	3m	6.7	Medium
1/5	1m 50s	6.4	Medium
1/10	1m	5.5	Medium-soft
1/20	55s	4.8	Very soft
1/40			No gel formed

5 *Table 10: Effect of HSA/glutaric acid molar ratio using ethanol-modified HSA (molar ratio HSA/EDC of 1/70)*

<b>Molar ratio HSA/GA</b>	<b>Gelling time</b>	<b>pH of the gel</b>	<b>Gel Hardness</b>
1/0	8m	7.7	Soft
1/3.5	1m 30s	7.3	Medium
1/5	1m 5s	6.9	Medium-hard
1/10	32s	5.6	Hard
1/20	25s	5.1	Medium
1/40	23s	4.3	Soft

10 5.4.2 *Preparation of HSA gelling solution by reaction with glucose*

A gelling solution was prepared as in Example 5.4.1 but replacing ethanol with glucose in a final HSA/Glucose molar ratio of 1/15 and a final HSA/Glutaric acid molar ratio of 1/5.

The gels produced were softer than similar gels with no glucose, and the gelling time was reduced.

#### *5.4.3 Preparation of HSA gelling solution by addition of glycerol*

5

Glycerol was added to 20% HSA solution (USP) in volume percentages of 0 to 16.7. Gels were then prepared using the method described in Example 5.1.

10 The addition of glycerol decreases the gelling time and was shown to slow down the drying out of the gel when left uncovered at room temperature for a period of two weeks.

#### *5.4.4 Preparation of HSA gelling solution by addition of ethanol or glucose directly to gelling solution*

15

If either ethanol or glucose is added directly to the HSA solution, and then used to form gels in the method described in Example 5.1, a similar but less marked effect was seen to that of Examples 5.4.1 and 5.4.2 respectively, where an HSA pre-modification step with the additives was included.

20

#### Example 6: The effect of increasing the level of dicarboxylic acid on the stability of the formed gel

25 Increasing the levels of glutaric acid in the gelling solution has been shown to result in either the formation of initially medium to hard gels that revert to soft gels with time, or soft gels that redissolve to form viscous solutions. Control of this dissolution process could be a useful method of controlling delivery of drugs in the various applications described herein.

30 Gels were prepared following the method described in Example 5.1. The molar ratio of HSA to glutaric acid was varied from 1/5 to 1/35, at two molar ratios of HSA to EDC. Results are shown in Table 11 below.

As the ratio of glutaric acid increased, the gelling times decreased up to the point where no gel was formed. Intermediate levels produced gels that redissolved to form viscous solutions on standing. This was shown to be a result of pH changes during the reaction. At low levels of glutaric acid the pH of the gelling solution climbs to 6-7 after addition of EDC until the gel forms. At high levels of glutaric acid, the pH climbs initially then falls again towards an acidic pH of 5-6 causing the soft gel to redissolve or preventing a gel from forming.

10 *Table 11: Effect of glutaric acid level on the stability of gel formed*

<b>HSA/GA/EDC molar ratio</b>	<b>Gelling time</b>	<b>Gel properties</b>
1/5/35	9 min 20 sec.	Clear medium to soft gel
1/10/35	5 min 25 sec.	Soft gel becomes viscous solution after 10 min.
1/15/35	-----	No gel formed.
1/10/50	3 min	Very soft gel becoming very hard after 5-25 min, reverting to a medium gel overnight.
1/15/50	2 min 45 sec.	Very soft gel becoming very hard in 4-8 min, reverting to a soft gel overnight
1/20/50	2 min 30 sec.	Soft gel becoming medium to hard in 4 min, forming a viscous solution after 1 hr.
1/25/50	2min 30 sec.	Soft gel becoming medium after 4 min, forming a viscous solution after 30 min.
1/30/50	3 min	Very soft gel becoming viscous solution after 7 min.
1/35/50	-----	No gel formed

Example 7: Controlling gel pH

The gelling reaction is best performed at acidic pH. It is possible to raise the pH of  
5 the final gel to close to physiological pH. There are two ways of controlling gel pH. One approach is to vary the molar ratio of HSA to the dicarboxylic acid; low levels of dicarboxylic acid give gels of close to physiological pH. The second approach is to vary the molar ratio of HSA to EDC, with high EDC levels resulting in gels of higher pH. For those skilled in the art it can be seen that it is possible to find a  
10 balance of conditions that achieves the required gel consistency for a particular application at the desired pH.

**7.1 Controlling pH of gels using different concentrations of dicarboxylic acids**

15 Gels were prepared by dissolving glutaric acid in 20% HSA solution (USP) and adding a solution of EDC in distilled water to give a final HSA concentration of 166mg/ml. Molar ratios of HSA to EDC of 1:35 and 1:70 were used. The results are shown in Tables 4 and 5 above.

20 At these EDC levels, gels can be formed using a molar ratio of HSA to glutaric acid of 1:20 or less. At higher levels of dicarboxylic acid the gels are unstable if they form at all, as discussed in Example 6. Gel pH values in the range of 5.3 to 7.6 were obtained.

**25 7.2 pH control of gels using varying levels of EDC**

Gels were prepared by dissolving glutaric acid in 20% HSA solution (USP) at a HSA to glutaric acid molar ratio of 1:10. Solutions of EDC in distilled water were added to give a final concentration of HSA of 166mg/ml and molar ratios of HSA to  
30 EDC of 1:35 to 1:80. Results are shown in Table 6 above.

Gel pH values in the range of 5.6 to 6.6 were achieved by varying the levels of EDC. This is also supported by a comparison of the data in Tables 4 and 5 above. Increasing the levels of EDC in the gelling mixture also results in shorter gelling times and harder gels.

5

Example 8: Production of a bioadhesive

The bioadhesive gel was prepared either as a liquid or a dry powder. The tensile strength was measured by applying the liquid or powder between two pieces of meat (3cm<sup>2</sup> beefsteak). One piece of meat was attached to card and could be held in place by a clamp and stand. Weights were attached to the second lower piece of meat to measure the tensile strength. The meat was incubated at 37°C for 5 minutes prior to addition of weights.

15 8.1 HSA (4ml 20%; BPL, Zenalb) was mixed with glutaric acid and EDC at a ratio of 1/50/100 respectively.

The measured tensile strength was 63mg/mm<sup>2</sup>.

20 8.2 A dry powder formulation was prepared by mixing 200mg freeze dried HSA (Sigma) with glutaric acid and EDC in a molar ratio of either 1/50/100 or 1/60/140 respectively.

The tensile strength increased with an increase in ratio of spacer and EDC.

25 The 1/50/100 blend gave a tensile strength of ~180mg/mm<sup>2</sup>.  
The 1/60/120 blend gave a tensile strength of ~280mg/mm<sup>2</sup>.

Example 9: Release of drugs from gel (tetracycline)

To 1ml 20% HSA solution was added 150µl of a 10mg/ml solution of tetracycline in ethanol. Gels were formed as described in previous examples above using molar 5 ratios of HSA/glutaric acid/EDC of 1/30/60 and 1/40/80 respectively. The gel was left overnight before being placed in a vial containing 5ml distilled water. The release of tetracycline with time was measured at 364nm (Figure 2).

Example 10: Stability of HSA gelling solutions

10

10.1 Stability of ethanol-modified HSA gelling solution at 4°C and room temperature

Ethanol-modified HSA gelling solution (prepared as described in Example 5.4.1) 15 was sterile filtered through a 0.22µm filter. Half of the solution was stored at 4°C and half at room temperature, in sealed vials. On days 0, 7, 21 and 28, aliquots of the solutions were reacted with aqueous EDC solution, and the gelling time, gel characteristics, pH and gel stability were compared.

20 *Table 12: Storage of gelling solution at 4°C*

Day	Gelling Time	Gel Characteristics
0	2min 10sec	Clear medium/hard gel
7	2min 15 sec	Clear medium/hard gel
21	2min	Clear medium/hard gel
28	2min 15 sec	Clear medium/hard gel

All gels prepared were held in sealed vials at 37°C for 14 days, to compare gel stability; none showed any sign of deterioration or bacterial growth in this period.

25

*Table 13: Storage of gelling solution at room temperature*

Day	Gelling Time	Gel Characteristics	Gel pH
0	2min 10sec	Clear medium/hard gel	6.9
7	2min 10sec	Clear medium/hard gel	6.9
21	2 min	Clear medium/hard gel	7.0
28	2min 10sec	Clear medium/hard gel	6.9

This data demonstrates that the ethanol-modified HSA gelling solution is stable for  
 5 at least 4 weeks at 4°C and at room temperature.

**10.2 Stability of glucose-modified HSA gelling solution at 4°C and at room temperature**

10 The above experiment was repeated using glucose-modified HSA gelling solution (as described in Example 5.4.2). The solution stored at room temperature was shown to be stable for 2 weeks. The solution stored at 4°C was shown to be stable for at least 4 weeks.

15 **10.3 Stability of HSA/glutaric acid solution at 4°C and at room temperature**

A solution of HSA (200mg/ml) and glutaric acid (molar ratio HSA/glutaric acid of 1/37) was shown to be stable for at least 4 weeks at 4°C and at room temperature, using the procedure described in Example 10.1.

20

**10.4 Stability of HSA/adipic acid solution at 37°C and at room temperature**

A solution of HSA (200mg/ml) and adipic acid (molar ratio HSA/adipic acid of 1/30) was shown to be stable for at least 3 weeks at 37°C and at room temperature, 25 using the procedure described in Example 10.1.

Example 11: Stability of formed gels

Gels with a molar ratio HSA/glutaric acid/EDC of 1/40/80, 1/50/100, 1/60/120 and 1/70/140 were held at 4°C, room temperature and 37°C in sealed vials for a 6 week period. All gels stored at 4°C and room temperature were stable for 6 weeks, although the turbidity of the higher ratio gels increased slightly after 4 weeks. All gels stored at 37°C were stable for 2 weeks. By 3 weeks these gels had increased in hardness and had become more turbid. None of the gels showed any signs of bacterial growth.

10

Example 12: *In situ* application of gel

Wells (2cm<sup>2</sup> and 0.5cm deep) were cut into pieces of pig skin in vitro. Gels (prepared as described in Example 5.1 above) were formed in situ in the wells, covered with a vapour permeable membrane (eg Tagaderm, 3M) and incubated at 37°C. The gels remained soft and did not dry out. They were easily removed from the "wound" attached to the membrane.

Claims

1. A method of forming a wound dressing, which method comprises forming a protein polymer by reacting a protein with a polyfunctional spacer, or an activated derivative thereof.  
5
2. A method as claimed in Claim 1, wherein the protein polymer is formed *in situ*.
- 10 3. A method as claimed in Claim 1, wherein the protein polymer is formed prior to application.
4. A method as claimed in Claim 3, wherein a supporting substrate is incorporated into the dressing.  
15
5. A method as claimed in Claim 3 or 4, wherein the dressing is in the form of a bandage or gel sheet.
- 20 6. A method as claimed in any preceding claim, further comprising the application to the wound dressing of a vapour-permeable membrane.
7. A method as claimed in any preceding claim, wherein the protein is a globular protein.  
25
8. A method as claimed in any one of Claims 1 to 6, wherein the protein is a fibrous protein.
9. A method as claimed in Claim 7, wherein the globular protein is a serum protein.  
30
10. A method as claimed in Claim 9, wherein the protein is albumin.

11. A method as claimed in Claim 10, wherein the albumin is human serum albumin.

12. A method as claimed in Claim 1, wherein the protein is blood-derived.

5

13. A method as claimed in Claim 1, wherein the protein is a recombinant product.

14. A method as claimed in any preceding claim, wherein the spacer is selected  
10 from the group consisting of polycarboxylic acids, polyamines,  
poly(carboxy/amino) compounds, polyalcohols, polyketones, polyaldehydes and  
polyesters.

15. A method or wound dressing as claimed in Claim 14, wherein the spacer is  
15 a polycarboxylic acid.

16. A method as claimed in Claim 15, wherein the polycarboxylic acid is a  
dicarboxylic acid.

20 17. A method as claimed in Claim 16, wherein the dicarboxylic acid is an  
alkylene dicarboxylic acid.

18. A method as claimed in any preceding claim, wherein the spacer is  
activated to facilitate reaction with the protein molecules.

25

19. A method as claimed in Claim 18, wherein the activating agent is a  
carbodiimide compound.

20. A method as claimed in Claim 19, wherein the carbodiimide compound is  
30 ethyl[dimethyleminopropyl]-carbodiimide.

21. A wound dressing prepared by the method of any preceding claim.
22. A wound dressing comprising a protein polymer formed by reacting a protein with a polyfunctional spacer, or an activated derivative thereof.
- 5 23. A wound dressing as claimed in Claim 22, which is formed *in situ*, by reaction of the protein and polyfunctional spacer, or activated derivative thereof, at the wound site.
- 10 24. A wound dressing as claimed in Claim 22, which is preformed, prior to application of the dressing to the wound site.
25. A wound dressing as claimed in Claim 24, which comprises a bandage impregnated with the protein polymer.
- 15 26. A wound dressing as claimed in Claim 24, which is in the form of a gel sheet.
27. A wound dressing as claimed in Claim 25, in which the gel sheet has a supporting substrate.
- 20 28. A wound dressing as claimed in any one of Claims 21 to 27, which further comprises one or more therapeutically active agents.
- 25 29. A wound dressing as claimed in Claim 28, wherein the therapeutically active agents are selected from the group consisting of antibiotics, antivirals, anti-inflammatory agents, pain killers, haemostatic agents, phages, growth factors, anti-scarring agents, odour-absorbing agents, and agents that promote angiogenesis.


30. A method of forming a protein polymer, which method comprises reacting a protein with a dicarboxylic acid or an activated derivative thereof, provided that the protein is not bovine serum albumin.

5 31. A method of forming a protein polymer, which method comprises reacting a protein with an alkylene dicarboxylic acid or an activated derivative thereof.

32. A method as claimed in Claim 30 or Claim 31, wherein the protein is an albumin.

10 33. A method as claimed in Claim 32, wherein the protein is human serum albumin.

34. A method as claimed in any one of Claims 30 to 33, wherein the  
15 dicarboxylic acid has the formula



in which n is from 1 to 20, preferably from 2 to 12, and more preferably from 3 to 8.

20 35. A method as claimed in any one of Claims 30 to 34, wherein the dicarboxylic acid is activated with a carbodiimide activating agent.

36. A method as claimed in Claim 35, wherein the activating agent is  
25 ethyl[dimethyleminopropyl]-carbodiimide.

37. A protein polymer formed by reacting a protein with a dicarboxylic acid or an activated derivative thereof, provided that the protein is not bovine serum albumin.

30 38. A protein polymer formed by reacting a protein with an alkylene dicarboxylic acid or an activated derivative thereof.

39. A protein polymer as claimed in Claim 37 or Claim 38, which is in the form of a solution.

5 40. A protein polymer as claimed in Claim 37 or Claim 38, which is in the form of insoluble particles.

41. A protein polymer as claimed in Claim 37 or Claim 38, which is in the form of a gel.

10 42. A use of a protein polymer as claimed in any one of Claims 37 to 41 in the delivery of one or more therapeutically active components to the body.

15 43. A use of a protein polymer as claimed in Claim 41 in the topical treatment of a wound, burn or ulcer.

44. A use as claimed in Claim 43, wherein the protein polymer is applied to the wound, burn or ulcer as a preformed gel.

20 45. The use as claimed in Claim 43, wherein a protein and a dicarboxylic acid spacer are applied in solution to the wound, burn or ulcer, and the protein polymer is formed *in situ*.

25 46. The use of a protein polymer as claimed in Claim 37 or Claim 38 as a coating for a device to be implanted in the body.

47. The use of a protein polymer as claimed in Claim 39 as a platelet substitute or platelet enhancer.

30 48. A protein polymer as claimed in Claim 39, wherein the protein polymer is conjugated with one or more clotting agents or active peptide derivatives.

49. A protein polymer as claimed in Claim 48, wherein the protein polymer is conjugated with fibrinogen.

50. A protein polymer as claimed in Claim 39, which polymer is conjugated to a 5 therapeutically active agent, or a precursor thereof, and to a targeting moiety having an affinity with a specific locus within the body.

51. The use of a conjugate as claimed in Claim 50 in targeted anti-cancer therapies.

10 52. A protein polymer as claimed in Claim 39, which polymer is conjugated to a contrast agent and to a targeting moiety having an affinity with a specific locus within the body.

15 53. The use of a conjugate as claimed in Claim 39 in medical imaging applications.

54. A kit for the preparation of a wound dressing according to Claim 21 or Claim 22, which kit comprises a first composition and a second composition, the first composition and the second composition being held in separate containers such 20 that reaction between the first composition and the second composition is prevented.

55. A kit as claimed in Claim 54, wherein the first composition comprises the protein and the polyfunctional spacer, and the second composition comprises an 25 activator for the polyfunctional spacer.

56. A kit as claimed in Claim 55, wherein the first composition is a solution and the second composition is a powder.

57. A method of treatment of the human or animal body, which method 30 comprises the administration to the body of a protein polymer as claimed in any one of Claims 37 to 41.

58. A method as claimed in Claim 57, wherein the protein polymer is administered intravenously.

59. A method as claimed in Claim 57, wherein the protein polymer is administered topically.



60. A method as claimed in any one of Claims 57 to 59, wherein the protein polymer is administered in the form of a solution.

10 61. A method as claimed in Claim 59, wherein the protein polymer is administered in the form of a powder.

62. A method as claimed in Claim 59, wherein the protein polymer is administered in the form of a gel.

15 63. A method as claimed in Claim 59, wherein the protein and the dicarboxylic acid cross-linking agent are administered to the body, such that the protein polymer is formed *in situ*.

1/1

Figure 1Figure 2

# INTERNATIONAL SEARCH REPORT

PCT/GB2005/000566

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61L15/60 A61L17/06 A61L27/22 A61L15/32

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 A61L A61K C08L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	US 5 733 563 A (FORTIER ET AL) 31 March 1998 (1998-03-31)  column 1, line 10 - line 16 column 4, line 18 - line 30 column 8, line 54 - line 60 claims 1-5,12  ----- US 2003/211137 A1 (SIERRA DAVID) 13 November 2003 (2003-11-13)  page 1, paragraph 11 page 1, paragraph 17 - page 2, paragraph 19 page 3, paragraph 32 page 3, paragraph 34 - paragraph 37 claims 1-28  ----- -/--	1,3-12, 18,21, 22,24-29
X		1-13,18, 21-29, 54-56

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

28 July 2005

Date of mailing of the international search report

10/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel: (+31-70) 340-2040, Tx: 31 651 epo nl  
 Fax: (+31-70) 340-3016

Authorized officer

Menidjel, R

## INTERNATIONAL SEARCH REPORT

PCT/GB2005/000566

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category	Relevant to claim No.
X	<p>US 5 412 076 A (GAGNIEU ET AL) 2 May 1995 (1995-05-02)</p> <p>column 1, line 35 - line 53 column 2, line 21 - line 48 column 4, line 11 - line 36 column 5, line 66 - column 10, line 44 examples 10,11</p> <p>-----</p> <p>WO 99/66964 A (SURGICAL SEALANTS, INCORPORATED; TAMMISHETTI, SHEKHARAM; PENDHARKAR, S) 29 December 1999 (1999-12-29) cited in the application the whole document</p> <p>-----</p> <p>EP 0 807 441 A (NYCOMED IMAGING AS) 19 November 1997 (1997-11-19)</p> <p>column 3, line 31 - column 4, line 6 column 4, line 30 - line 56 column 5, line 40 - line 46 claims 1-15</p> <p>-----</p> <p>WO 2005/063311 A (SANGUIBIO TECH GMBH; TESLENKO, ALEXANDER; NIKONOW, BORIS ALEKSEEVICH;) 14 July 2005 (2005-07-14)</p> <p>page 7, line 20 - page 8, line 29 page 14, line 23 - page 15, line 3 claims 1-6</p> <p>-----</p>
	30,31, 34-47, 50-52, 57-63
X	30-42, 57,59-62
X	30-41, 53,57-63
E	1,3-8, 14,15, 18,21, 22,24-29

**INTERNATIONAL SEARCH REPORT**

PCT/GB2005/000566

**Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 42–45, 47, 51–53, 57–63 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

PCT/GB2005/000566

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5733563	A	31-03-1998	AT AU WO DE DE DK EP ES PT	215106 T 1060495 A 9515352 A1 69430243 D1 69430243 T2 705298 T3 0705298 A1 2172573 T3 705298 T	15-04-2002 19-06-1995 08-06-1995 02-05-2002 17-10-2002 08-07-2002 10-04-1996 01-10-2002 31-07-2002
US 2003211137	A1	13-11-2003	AT AU CA DE DE EP JP	258808 T 4164401 A 2399211 A1 60101956 D1 60101956 T2 1257304 A1 2003523409 T	15-02-2004 03-09-2001 30-08-2001 11-03-2004 23-12-2004 20-11-2002 05-08-2003
US 5412076	A	02-05-1995	FR AT DE DE EP ES JP	2692582 A1 160798 T 69315483 D1 69315483 T2 0575273 A1 2113511 T3 6080935 A	24-12-1993 15-12-1997 15-01-1998 02-07-1998 22-12-1993 01-05-1998 22-03-1994
WO 9966964	A	29-12-1999	AU CA EP JP WO US US US US US	4711599 A 2335952 A1 1089769 A1 2002518135 T 9966964 A1 2005079999 A1 2004072756 A1 2004063613 A1 2005037960 A1 2002022588 A1	10-01-2000 29-12-1999 11-04-2001 25-06-2002 29-12-1999 14-04-2005 15-04-2004 01-04-2004 17-02-2005 21-02-2002
EP 0807441	A	19-11-1997	EP AT AT AU AU AU AU AU AU AU AU AU AU AU AU AU CA CA DE DE DE DE DK WO WO EP EP	0807441 A2 133158 T 157547 T 663488 B2 1428392 A 663866 B2 1443992 A 701817 B2 4094196 A 1100808 A3 2107106 A1 2107107 A1 69207758 D1 69207758 T2 69222037 D1 69222037 T2 576521 T3 9217213 A1 9217436 A1 0577659 A1 0576521 A1	19-11-1997 15-02-1996 15-09-1997 12-10-1995 02-11-1992 26-10-1995 02-11-1992 04-02-1999 04-04-1996 28-12-1999 29-09-1992 29-09-1992 29-02-1996 20-06-1996 09-10-1997 15-01-1998 20-04-1998 15-10-1992 15-10-1992 12-01-1994 05-01-1994

## INTERNATIONAL SEARCH REPORT

PCT/GB2005/000566

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0807441	A	ES	2082459 T3	16-03-1996
		ES	2106857 T3	16-11-1997
		FI	934227 A	27-09-1993
		FI	934228 A	27-09-1993
		GR	3025333 T3	27-02-1998
		HK	1002624 A1	04-09-1998
		HK	1003569 A1	30-10-1998
		IE	921010 A1	07-10-1992
		IE	980188 A1	23-02-2000
		JP	6505981 T	07-07-1994
		JP	6508108 T	14-09-1994
		NO	933430 A	08-11-1993
		NO	933432 A	27-09-1993
		SG	47687 A1	17-04-1998
		US	2003031629 A1	13-02-2003
		US	5529766 A	25-06-1996
		US	5919753 A	06-07-1999
		US	2004131549 A1	08-07-2004
WO 2005063311	A	14-07-2005	RU 2240830 C1	27-11-2004
			WO 2005063311 A1	14-07-2005